Skip to main content
. Author manuscript; available in PMC: 2007 Feb 16.
Published in final edited form as: J Allergy Clin Immunol. 2006 Jul;118(1):257–268. doi: 10.1016/j.jaci.2006.04.039

FIG 3.

FIG 3

DSS treatment induces experimental colitis in WT and RELM-β-/- mice. A, Northern blot analysis of RELM-β mRNA expression in the colons of control (top panel) and DSS-treated (middle panel) WT mice and kinetics (days 0-8) of RELM-β mRNA expression in the colons of WT mice and IL-13-/- mice (bottom panel) on day 7. Total RNA is shown by ethidium bromide (EtBr) staining. DAI (B), weight change (C), diarrhea-rectal bleeding score (D), and colon length (E; day 7) of control- and DSS-treated WT and RELM-β-/- mice. F, The percentage survival during the course of DSS treatment in WT and RELM-β-/- mice. Data in Fig 3, B through F, represent the mean 6 SEM of 4 to 5 mice per group from triplicate experiments. Statistical significance of differences was determined by using the Kruskal-Wallis test (*P < .05).